Irinotecan Hydrochloride

SKU: orb1310566

Description

Irinotecan Hydrochloride (CPT-11 hydrochloride) is a prodrug converted to the potent topoisomerase I inhibitor SN-38, causing S-phase-specific DNA damage and apoptosis. It is widely used in cancer research for in vitro cytotoxicity assays and in vivo xenograft studies, particularly for colorectal and pancreatic cancer models.

Research Area

Cell Biology, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 100286-90-6
• MW: 623.14
• Purity: 98.00% (May vary between batches)
• Formula: C₃₃H₃₉ClN₄O₆
• SMILES: Cl.CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12
• Target: Topoisomerase,Autophagy
• Solubility: DMSO:65 mg/mL (104.31 mM);H2O:3.12 mg/mL (5.01 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (8.02 mM)

Bioactivity

• In Vivo:
  The time course of body weight change after Irinotecan (100 mg/kg i.p.) injection shows a significant dosing time-dependent difference (P<0.01). Mean maximum body weight loss is observed between days 3 and 4 after Irinotecan (CPT-11) injection. The minimum mean body weight loss is observed after Irinotecan (CPT-11) injection at 1700 hr. Moreover, the maximum mean body weight loss is observed after Irinotecan injection at 0500 or 0900 hr.
• In Vitro:
  Increasing concentrations of Irinotecan (0.1, 1, 10, 100, and 1000 μg/mL) inhibits the growth of all cell lines in a dose-dependent manner. COLO-357 cells are most sensitive and HT29 most resistant to Irinotecan in the MTT assay on incubation for 90 min. The IC50 concentrations are 100, 50, 5.4, 23 and 46 μg/mL Irinotecan for HT29, NMG 64/84, COLO-357, MIA PaCa-2 and PANC-1, respectively.
• Cell Research:
  Irinotecan hydrochloride is dissolved in DMSO and stored, and then diluted with appropriate medium before use. To determine the effects of Irinotecan in combination with 5-FU, the MTT assay is used. Depending on the cell lines, 10,000 to 20,000 cells per well are seeded in 96-well plates and incubated for 24 h in complete medium. On day 2, cells are incubated in the absence or presence of Irinotecan for 30 min followed by 5-FU for 24 h. After another 24 h in complete medium without any additives, MTT reagent is added on day 4 to initiate the assay and the cells are incubated for an additional 4 h at 37°C. After removal of the medium and dissolving the crystals with acidified isopropanol, the samples are analyzed using an ELISA plate reader at 570 nm. The value at 650 nm is subtracted as background.

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CPT11 Hydrochloride, CPT-11 Hydrochloride, CPT-11 hydrochloride, CPT11, CPT-11, CPT 11, CPT 11 Hydrochloride, (+)-Irinotecan, Camptothecin 11 Hydrochloride, Camptothecin 11 hydrochloride, Autophagy, Inhibitor, inhibit, Irinotecan, Irinotecan Hydrochloride, Topoisomerase, Topo I

Compound Identifiers

PubChem CID

74990